Press ReleaseAIMHI_wpuser2024-08-29T11:16:30+00:00

Press Release

Press Release

Tvardi Therapeutics Announced Closing of Merger with Cara Therapeutics

Ellaye2025-04-18T14:56:49+00:00April 18, 2025|Press Release|

Register! FREE Legal Seminars for Early-Stage Biotechs

Ellaye2025-04-16T18:33:18+00:00April 7, 2025|Press Release|

2025 Venture Competitions Are Open Now for Early-Stage Oncology Companies Worldwide!

Ellaye2025-04-11T16:51:59+00:00January 3, 2025|Press Release|

2024 NFCR Global Summit Highlights | Co-hosted by AIM-HI

Ellaye2025-02-21T15:59:23+00:00October 25, 2024|Press Release|

AIM-HI Accelerator Fund Welcomes New Board Member, Silas Deane

Ellaye2025-02-21T15:59:23+00:00October 22, 2024|Press Release|

The world’s top cancer experts, entrepreneurs, and advocates to join NFCR and AIM-HI on October 18th, 2024, in Washington, DC

Ellaye2025-02-21T15:59:23+00:00September 27, 2024|Press Release|

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Address:

5515 Security Lane, Suite 1105
Rockville, MD 20852

Email:

info@aim-hiaccelerator.org

Phone:

1-800-321-CURE (2873)

what we do

Copyright © AIM-HI 2025 All Rights Reserved

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Copyright © AIM-HI 2025 All Rights Reserved